Berman Jonathan Josh
Expert Opin Drug Metab Toxicol. 2008 Sep;4(9):1209-16. doi: 10.1517/17425255.4.9.1209.
Miltefosine is the first recognized oral treatment for leishmaniasis. It was first registered, in 2002, for Indian visceral leishmaniasis, and was reviewed by the present author in 2005.
Miltefosine is now being used for the full range of clinical leishmaniasis. The present review addresses non-clinical and clinical advances since 2005.
PubMed was accessed for all articles on miltefosine from 2005 to 2008.
RESULTS/CONCLUSIONS: Miltefosine is effective and can be recommended for visceral disease in India and in Ethiopia, and for cutaneous disease in Colombia and Bolivia. For unusual forms of disease that require long periods of treatment such as diffuse cutaneous leishmaniasis and post-kala-azar dermal leishmaniasis, oral miltefosine is probably the treatment of choice.
米替福新是首个被认可的用于治疗利什曼病的口服药物。它于2002年首次获批用于治疗印度内脏利什曼病，本文作者于2005年对其进行了综述。
米替福新目前正被用于治疗各种临床利什曼病。本综述阐述了自2005年以来在非临床和临床方面取得的进展。
检索了PubMed上2005年至2008年期间所有关于米替福新的文章。
结果/结论：米替福新有效，可推荐用于治疗印度和埃塞俄比亚的内脏利什曼病，以及哥伦比亚和玻利维亚的皮肤利什曼病。对于需要长期治疗的特殊类型疾病，如弥漫性皮肤利什曼病和黑热病后皮肤利什曼病，口服米替福新可能是首选治疗方法。
